These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3089001)

  • 1. Challenging conventional aminoglycoside dosing regimens. The value of experimental models.
    Kapusnik JE; Sande MA
    Am J Med; 1986 Jun; 80(6B):179-81. PubMed ID: 3089001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches for the use of aminoglycosides: the value of experimental models.
    Kapusnik JE; Sande MA
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():7-10. PubMed ID: 3710965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.
    Kapusnik JE; Hackbarth CJ; Chambers HF; Carpenter T; Sande MA
    J Infect Dis; 1988 Jul; 158(1):7-12. PubMed ID: 3392422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.
    Powell SH; Thompson WL; Luthe MA; Stern RC; Grossniklaus DA; Bloxham DD; Groden DL; Jacobs MR; DiScenna AO; Cash HA; Klinger JD
    J Infect Dis; 1983 May; 147(5):918-32. PubMed ID: 6860416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.
    Rusnak MG; Drake TA; Hackbarth CJ; Sande MA
    J Infect Dis; 1984 Jun; 149(6):980-5. PubMed ID: 6429255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria.
    Klastersky J; Thys JP; Mombelli G
    Rev Infect Dis; 1981; 3(1):74-83. PubMed ID: 7013002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
    Marsot A; Hraiech S; Cassir N; Daviet F; Parzy G; Blin O; Papazian L; Guilhaumou R
    Int J Antimicrob Agents; 2020 Oct; 56(4):106124. PubMed ID: 32739478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas infections.
    Quinn EL; Burch KH; Cox F; Fisher E; Madhavan T; Haas EJ; Del Busto R
    Am Fam Physician; 1976 Nov; 14(5):84-91. PubMed ID: 824948
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
    Schiff JB; Small GJ; Pennington JE
    Antimicrob Agents Chemother; 1984 Jul; 26(1):1-4. PubMed ID: 6433786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
    Pennington JE; Johnson CE
    Antimicrob Agents Chemother; 1982 Sep; 22(3):406-8. PubMed ID: 6814354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA; Nagel JL
    Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    J Antimicrob Chemother; 1997 Jun; 39(6):677-86. PubMed ID: 9222035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.
    DeJace P; Klastersky J
    Am J Med; 1986 Jun; 80(6B):29-38. PubMed ID: 3524218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies of dosing regimens and combination effects of aminoglycosides and beta-lactam in an experimental Pseudomonas aeruginosa infection in mice].
    Kikuchi K
    Kansenshogaku Zasshi; 1991 Feb; 65(2):216-25. PubMed ID: 2066605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration.
    Makhoul IR; Merzbach D; Lichtig C; Berant M
    J Infect Dis; 1993 Nov; 168(5):1296-9. PubMed ID: 8228367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia.
    Gordin FM; Rusnak MG; Sande MA
    Antimicrob Agents Chemother; 1987 Mar; 31(3):398-403. PubMed ID: 3107461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.